2 completed, 1 withdrawn. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Forest Hills Lab: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients. Gemfibrozil, Placebo - Parkinson Disease | Phase 2 | Withdrawn | Forest Hills Lab | 2027-11-01 | 2026-08-19 | |
| Safety and Tolerability of Glyceryl Tribenzoate (GTB) Capsules in Healthy Subjects Glyceryl Tribenzoate - Neurological Disorder | Phase 1 | Completed | Forest Hills Lab | 40 | 2022-12-12 | 2025-10-16 |
| Clinical Trial to Study the Efficacy and Safety of Rejeunesse Shape With Lidocaine (HA Filler) in Treating Healthy Subjects Rejeunesse, Restylane Perlane - Nasolabial Fold Correction | Phase 3 | Completed | Forest Hills Lab | 71 | 2016-02-15 | 2026-08-18 |
Nervous System Diseases (1) · Parkinson Disease (1)
Gemfibrozil (1) · glyceryl tribenzoate (1)
United States (1)